These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33854299)

  • 41. Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial.
    Sohn IS; Kim CJ; Oh BH; Hong TJ; Park CG; Kim BS; Chung WB;
    Am J Cardiovasc Drugs; 2016 Apr; 16(2):129-38. PubMed ID: 26691333
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
    Chin KM; Sitbon O; Doelberg M; Feldman J; Gibbs JSR; Grünig E; Hoeper MM; Martin N; Mathai SC; McLaughlin VV; Perchenet L; Poch D; Saggar R; Simonneau G; Galiè N
    J Am Coll Cardiol; 2021 Oct; 78(14):1393-1403. PubMed ID: 34593120
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Erratum: Short-Term Efficacy of Calcium Fructoborate on Subjects with Knee Discomfort: a Comparative, Double-Blind, Placebo-Controlled Clinical Study [Corrigendum].
    Clin Interv Aging; 2021; 16():203. PubMed ID: 33564230
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study.
    Fogari R; Taddei S; Holm-Bentzen M; Baszak J; Melani L; Schumacher K
    Clin Drug Investig; 2010; 30(9):581-97. PubMed ID: 20593911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension.
    Gleim GW; Rubino J; Zhang H; Shahinfar S; Soffer BA; Lyle PA; Littlejohn TW; Feig PU
    Clin Ther; 2006 Oct; 28(10):1639-48. PubMed ID: 17157119
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Erratum: Effect of a cod protein hydrolysate on postprandial glucose metabolism in healthy subjects: a double-blind cross-over trial - CORRIGENDUM.
    Dale HF; Jensen C; Hausken T; Lied E; Hatlebakk JG; Brønstad I; Hoff DAL; Lied GA
    J Nutr Sci; 2019; 8():e1. PubMed ID: 30719283
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.
    Calhoun DA; Lacourcière Y; Chiang YT; Glazer RD
    Hypertension; 2009 Jul; 54(1):32-9. PubMed ID: 19470877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Erratum: Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum].
    Neuropsychiatr Dis Treat; 2015; 11():863. PubMed ID: 25848284
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
    McGill JB; Reilly PA
    Clin Ther; 2001 Jun; 23(6):833-50. PubMed ID: 11440284
    [TBL] [